Share on StockTwits

OHR Pharmaceutical (NASDAQ:OHRP) Director June Sherie Almenoff purchased 2,200 shares of the stock in a transaction dated Wednesday, September 3rd. The stock was purchased at an average price of $8.08 per share, for a total transaction of $17,776.00. Following the completion of the acquisition, the director now directly owns 127,566 shares of the company’s stock, valued at approximately $1,030,733. The acquisition was disclosed in a document filed with the SEC, which is available at this link.

OHR Pharmaceutical (NASDAQ:OHRP) traded down 1.77% on Thursday, hitting $7.77. The stock had a trading volume of 116,532 shares. OHR Pharmaceutical has a 52-week low of $6.01 and a 52-week high of $20.00. The stock’s 50-day moving average is $8.5 and its 200-day moving average is $10.56. The company’s market cap is $193.2 million.

Separately, analysts at Brean Capital raised their price target on shares of OHR Pharmaceutical from $21.00 to $34.00 in a research note on Tuesday, June 24th. They now have a “buy” rating on the stock.

Ohr Pharmaceutical Inc (NASDAQ:OHRP) is a biotechnology rollup company.

Receive News & Ratings for OHR Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OHR Pharmaceutical and related companies with Analyst Ratings Network's FREE daily email newsletter.